and is important for cell proliferation. Vertebrates carry two genes that encode two highly homologous EIF5A isoforms, EIF5A1 and EIF5A2. 7 To be emphasized, EIF5A2, which implied to be a new oncogene in many types of human cancer as some reports shown, 8 was focused on in our present study. Previous work showed that EIF5A is up-regulated in human PC tissues, and inhibition of EIF5A could decrease the PC growth. 9 In addition, overexpression of EIF5A
promotes PC cells metastasis. 10 The above findings had important implications for the role of EIF5A in PC.
The sonic hedgehog (sHH) signalling pathway plays an important role in pancreas development and differentiation. 11 sHH, via binding to Patched (PTCH), allows smoothened (SMO) to activate downstream factors such as Gli-1 and then regulates target gene expression. Presently, the sHH signalling pathway contributes to cancer cell proliferation, differentiation, metastasis and chemotherapy resistance. 12, 13 In the preliminary work, we occasionally found EIF5A
could regulate the expressions of sHH and Gli-1.
Gem, which is a successful compound, frequently is used in PC treatment. Although this drug is effective, its cytotoxic effects and drug resistance limit its application. 14, 15 Such limitation highlights the necessity for exploiting novel treatment strategies which may help overcome drug resistance and enhance tumour cell response to anticancer drugs. In a recent study, the sHH signalling pathway was partly involved in the resistance of PC cells to Gem. 12 Hence, the objective of this study was to exploit the relationship and molecular mechanisms between EIF5A expression and the activation of sHH signalling pathway in PC. Moreover, we attempted to investigate the biological role of EIF5A in PC chemoresistance in vivo and in vitro.
| MATERIAL S AND ME THODS

| Tissue samples
With the approval and support of the Xi'an Jiaotong University ethics committee, the PC samples from patients (n = 30) with the pathological diagnosis were collected at First Affiliated Hospital of Xi'an Jiaotong University. The normal pancreas tissues were obtained from the donor for liver transplantation. All patients were informed and consent was obtained for the research. The nude mice, provided by animal experiment centre of Xi'an Jiaotong University, were used to construct the animal model. All experimental protocols were approved by the Ethical Committee of the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 
| Cell culture and reagents
| Immunohistochemistry
Pancreas samples from patients or nude mice were collected and la- 
| Immunofluorescence staining
EIF5A localization in PC cells was examined by immunofluorescence.
The prepared cells were washed three times with PBS and then fixed with 100 mL 4% paraformaldehyde in PBS. The cells were permeabilized in blocking buffer (0.1% Triton-X 100 or 0.1%-0.5% saponin, 10% NGS, 100 mmol/L PBS, pH 7.4) for 1 hour at room temperature and then incubated with primary antibody to HO-1 overnight at 4°C. The following day, the cells were washed and incubated with FITC-conjugated goat antimouse IgG (green fluorescence; 1:500, antimouse, #115165003; Jackson ImmunoResearch, West Grove, PA, USA) for 1 hour at room temperature. The cell nucleus was stained with DAPI (#0100-20; SouthernBiotech, Birmingham, AL, USA) for 10 minutes. After washing with PBS three times, cells were blocked for 5 minutes. As a negative control, the primary antibody was substituted with antibody diluent.
| Transfection
Tumour cells were transfected with EIF5A siRNA. Cells were seeded into small dishes and transfected with 100 nmol/L ShRNA using 
| Western blotting and real-time PCR
Western blotting and real-time PCR were performed as described previously. Briefly, protein was extracted from the cells using lysis 
| MTT assay
Cell proliferation rate was measured by MTT assays. Briefly, the 
| Orthotopic implantation experiments
Prepared PC cells were injected into the pancreases of nude mice exposed by midline laparotomy (4-6 sites; 20 μL total volume at a total concentration of 1 × 10 6 /μL). After 4 weeks, the tumour model was highly successful (85%), and drug treatment could be tested. Then, the nude mice were subsequently killed at the indicated time-points to assess the weight of primary tumours.
| Drug treatments
In vitro, recombinant sHH was applied to PC cells at 5 mg/mL.
Cyclopamine (Cyc), a sHH pathway inhibitor, was diluted to 18 μg/ mL and incubated with cells. The neutralizing antibody of sHH (anti-sHH, ab171018) was applied to PC cells at 30 μg/mL. Gem was purchased from Sigma-Aldrich and applied according to the PC cell EC50 (100 μg/mL). All of above were used to cells for 24 hours before being processed. In vivo, recombinant sHH, Cyc and Gem were applied to nude mice at 25, 45 and 125 mg/kg respectively, by intraperitoneal injection.
| Statistics
The analyses of the results were carried out using the SPSS statistical software package (version 13.0). The significance of the data was determined using a Student's t test. A value of P < 0.05 was considered to indicate a statistically significant difference. Data are representative of at least three independent experiments and are reported as means ± SD.
| RE SULTS
| EIF5A was increased in human PC tissues and PC cells
To determine whether EIF5A plays a role in the progression of PC, the expression of EIF5A proteins in normal and PC tissues was immunohistochemically stained with antibody of EIF5A ( Figure 1A and 
| Knockdown of EIF5A in PC cells suppressed the PC proliferation ability
To determine whether EIF5A plays an important role in the PC cells proliferation ability, the Panc-1and BxPc-3 cells were prepared for transfection with or without stable EIF5A knockdown using with Si-EIF5A in tumour model ( Figure 3B ). In contrast, the normal Panc-1 cells had overexpression of EIF5A protein ( Figure 3C ). 
| EIF5A regulated sHH signalling pathway in PC cells
To determine whether sHH signalling pathway is the downstream effector of EIF5A in PC cell proliferation, firstly, we investigated whether the EIF5A knockdown can decrease the protein expression of sHH signalling factors in different PC cell lines ( Figure 4A and B).
As shown in Figure 4 , Western blotting was used to quantify protein levels, and the EIF5A knockdown obviously reduced the expres- Altogether, these data indicated that sHH signalling pathway may be a downstream of EIF5A but the sHH factor, independent of sHH canonical stimulation.
| Inhibition of EIF5A expression and sHH signalling pathway suppressed PC cells proliferation and tumour growth
Our above work showed that EIF5A regulated Gli-1 protein expression in PC cells. To determine the effect of EIF5A and sHH signalling pathway for PC cells proliferation, the Panc-1 and BxPc-3 cells with
Si-EIF5A were treated with recombinant sHH, or Cyc which is a sHH signalling pathway inhibitor. As shown in Figure 5A and B, the results revealed that treatment with sHH significantly increased cells proliferation, but the Si-EIF5A combined using Cyc could most obviously decrease the proliferative ability in comparison with control or the with Si-EIF5A combined using recombinant sHH could inhibit the proliferation significantly (P < 0.05). Hence, these results demonstrated that EIF5A and sHH signalling pathway may be co-involved in PC cells proliferation.
To determine the effect of EIF5A and sHH signalling on PC tumour growth in vivo, we assessed orthotopic tumour formation of Panc-1 cells with Si-EIF5A. After 4 weeks, the cells were treated with recombinant sHH, or Cyc, then, the average tumour mass of different cell groups was measured ( Figure 5C ). A similar result was also observed in tumour size, compared with PC cells proliferation. The sHH group showed a strongly increasing tumour growth, but the group of Si-EIF5A and Cyc displayed the most obviously adverse effect on tumour size ( Figure 5D) (P < 0.05). Collectively, these results demonstrated that EIF5A
and sHH signalling pathway was sufficient and necessary for tumour growth in PC.
| The expression of EIF5A and activation of sHH signalling pathway were regulated by Gem in PC cells in vitro
To validate whether the EIF5A protein expression and sHH signalling changes is detected by Gem, we treated the PC cells with an EC50 
| Targeting EIF5A increased Gem sensitivity in PC in vitro and in vivo
In our previous work, we found that Gem leaded the up-regulation of EIF5A expression in PC cells. So, we hypothesized that EIF5A
could affect the sensitivity of Gem. Then, we examined PC cell proliferation ability when Panc-1 and BxPc-3 cells, with or without the Si-EIF5A, were treated with different concentrations of Gem for 24 hours. As shown in Figure 7A 
| D ISCUSS I ON
Pancreatic cancer remains one of the most aggressive malignancies, because of its poor prognosis, late diagnosis and rapid dissemination, with less than 7% survival at 5 years. 1 Most PC patients are detected at an advanced stage due to the difficulty of early diagnosis. is not effective for every PC patient at all stage of treatment. 17, 18 Although Gem is the most effective chemotherapeutic treatment against PC, its efficiency keeps in a lower rate. 19, 20 It was known that EIF5A was involved in transcription, mRNA turnover and nucleocytoplasmic transport in cells. Usually, it has two EIF5A isoforms, EIF5A1 and EIF5A2. EIF5A1 is the major isoform which is abundantly expressed in most cells. 8 EIF5A2 is expressed in few normal tissues but is overexpressed in tumour cells and even considered a candidate oncogene. 21 Based on above, EIF5A2 is chosen as our research focus in the study instead of EIF5A1. Important recent work has shown that EIF5A2 was high expression in PC and regulated the mechanisms of pathogenesis and metastasis. 16, 22 Therefore, in this work, the relationship and mechanism of EIF5A2 impacting with PC proliferation were discussed. Here, the results provided evidence that EIF5A was a major regulator controlling proliferation and chemosensitivity. 24, 25 A report showed that sHH signalling pathway could promote the pancreatic desmoplasia in PC cells. 26 As reported previously, sHH regulated pancreatic fibrosis and cancer cell proliferation and differentiation. 27, 28 We recently identified that sHH signalling pathway played a role in PC progress as a regulator to chemosensitivity. 12 Hence, inhibition of sHH signalling may be an attractive clinical target for therapeutic intervention. for Cyc group.) sHH could significantly increase cells proliferation. *P < 0.05, compared with control, # P < 0.05, compared with the Cyc group. C, Tumour size in mice was measured by the tumour weight, and the sHH group showed a strongly increasing tumour growth, but the group of Si-EIF5A and Cyc obviously decreases the tumour growth. D, Graphs showed that Si-EIF5A and sHH signalling could affect the tumour weight. *P < 0.05, compared with the control, # P < 0.05, compared with the sHH group, $ P < 0.05, compared with the group of
Si-EIF5A and Cyc
The data presented here demonstrated an important role for EIF5A in regulating PC proliferation 8, 17 in vitro and in vivo, and the inhibition of EIF5A enhanced the responsiveness of colorectal cancer to Gem. 18 Also, sHH signalling pathway was involved in the regulating process.
We reported that high expression of EIF5A protein was observed in PC. The immunohistochemical analyses demonstrated the up-regulation of EIF5A in PC tissues compared with normal pancreatic tissues. The immunofluorescence staining showed that EIF5A was identified in PC cells. Our found had the consistent aspect with that EIF5A protein was amplified in many neoplastic patient tissues. 16, 29, 30 The results suggested that EIF5A was involved in PC and may be a critical contributor to PC progression. Understanding the expression of EIF5A in PC is the study foundation for next research.
Then, the Panc-1 and BxPc-3 cells were transfected for stable knockdown EIF5A using shRNA. MTT results showed that the proliferation ability was significantly reduced upon EIF5A knockdown compared to control group. In fact, the reduced proliferation ability kept similar result at every time-point. Thus, these findings suggested that EIF5A played a role in PC cells proliferation ability, which was consistent with the idea that EIF5A contributes to tumour growth in other cancers. 23 Of cause, the MTT assays are not sufficiently convincing for promoting cell proliferation caused by EIF5A. Thus, we made further experiment in vivo to check the above results.
In this work, in order to investigate the tumour growth caused by Gli-1 in Si-EIF5A group. Altogether, these data indicated sHH factor was unnecessary in activation caused by EIF5A. Possibly the bypass activation or other transcriptional activation ways could be involved.
The internal mechanism will be solved in further study.
In following experiments, the growth results showed that sHH significantly increased cells proliferation, and the Si-EIF5A obviously decreased the proliferative ability. Together, these results demonstrated that EIF5A and sHH signalling pathway may be involved in and were necessary for tumour growth in PC, which is consistent with our pre-primary work.
Gem is frequently used in PC treatment. However, it is only marginally effective because of the less sensibility. 32 In this study, Gem significantly increased the expression of EIF5A and Gli-1 in PC cells.
The Si-EIF5A exhibited an obviously decreased proliferative ability when PC cells were treated with Gem. In vivo, the Panc-1 cells treated only with Gem showed a larger tumour size compared with Si-EIF5A group. These findings indicated that EIF5A played an important role in Gem sensitivity for PC. Therefore, these data imply that combination therapies involving Gem and EIF5A might be a promising strategy for PC.
In summary, our results revealed that EIF5A regulates the proliferation in PC through the SHH signalling pathway. Modulating the expression level of EIF5A could enhance the Gem sensitivity in PC.
Importantly, the target spot to EIF5A and SHH signalling pathway could benefit PC patients in future.
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F I G U R E 7
Inhibiting EIF5A increases Gem sensitivity. Proliferation ability of Panc-1 (A) and BxPc-3 cells (B) showed that the cell proliferation was dose-dependent on the concentration of Gem, and the PC cells with Si-EIF5A exhibited an obviously decreased proliferative ability compared with control group. C, Panc-1 cells treated only with Gem showed a larger tumour size compared with Si-EIF5A group. D, Graphs showed knockdown of EIF5A with Si-EIF5A obviously decreased the tumour growth. *P < 0.05 as determined by the Student's t test (n = 8 for each group.)
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